Patents by Inventor Mark G. Anderson

Mark G. Anderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240167426
    Abstract: A system includes a first sensor positioned to sense presence of a contrail in a first volume, wherein the first volume at least partially overlaps an expected volume of a contrail proximate an aircraft. A second sensor is positioned to sense a background reference in a second volume, where the second volume does not overlap the expected volume of a contrail proximate an aircraft. A controller is operatively connected to the first and second sensors. The controller includes machine readable instructions configured to cause the controller to utilize data input from both the first and second volumes to determine if a contrail is present from the aircraft. A system includes machine readable instructions configured to cause the controller to predict persistence of contrails on an intended route through the volume of airspace and to determine an improved route and/or propulsion operation to reduce contrail formation and persistence relative to the intended route.
    Type: Application
    Filed: November 21, 2022
    Publication date: May 23, 2024
    Applicant: Rosemount Aerospace Inc.
    Inventors: David L. Lincoln, Longke Wang, Jordan A. Snyder, Rodrigo Castillo-Garza, Sean C. Emerson, Darren G. Jackson, Mark D. Ray, Kaare Josef Anderson
  • Patent number: 11952597
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: April 9, 2024
    Assignee: Pfizer Inc.
    Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
  • Publication number: 20230402956
    Abstract: A hybrid photovoltaic-thermal system provides co-generation of electrical energy and thermal energy. Electrical energy is efficiently generated by photovoltaic panels that are cooled by heat exchangers attached thereto, and the cooling of the photovoltaic panels improves the energy output efficiency of the photovoltaic panels. The heat exchangers flow fluid through its channels, and the fluid collects heat from the photovoltaic panels to which the heat exchangers are attached. The heated fluid is then received at and stored in a thermal battery. The thermal battery can be a fluid tank that encourages the fluid to retain the heat collected from the photovoltaic panels. The thermal battery can then supply the heated fluid to thermal loads as thermal energy.
    Type: Application
    Filed: June 13, 2023
    Publication date: December 14, 2023
    Inventors: Brian Beachnau, Jarred Druzynski, Alexander Cauchon, Mark G. Anderson
  • Publication number: 20170348429
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: May 17, 2017
    Publication date: December 7, 2017
    Inventors: EDWARD B. REILLY, LOUIE NAUMOVSKI, CHRISTIAN B. ALLAN, JIEYI WANG, MARK G. ANDERSON, DANIEL E. AFAR
  • Publication number: 20100196907
    Abstract: The present invention relates to identifying the presence or absence of one or more copy number gains in the ABCB1 gene, the ABCB4 gene or combinations thereof, identifying patients eligible to receive Aurora kinase inhibitor therapy, either as monotherapy or as part of combination therapy, and monitoring patients' response to such therapy.
    Type: Application
    Filed: January 29, 2010
    Publication date: August 5, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Dimitri Semizarov, Jameel Shah, Jun Guo, Mark G. Anderson
  • Publication number: 20100028889
    Abstract: Methods for identifying cancer patients eligible to receive Bcl-2 family inhibitor therapy and for monitoring patient response to Bcl-2 family inhibitor therapy comprise assessment of the expression levels of the biomarker combinations set out in TABLES 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive Bcl-2 family inhibitor therapy and of determination of patient response to the therapy.
    Type: Application
    Filed: June 24, 2009
    Publication date: February 4, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Mark G. Anderson, Paul E. Kroeger, Saul H. Rosenberg, Stephen K. Tahir, John A. Wass, Christin Tse, Viswanath Devanarayan
  • Publication number: 20080199873
    Abstract: Methods for identifying cancer patients eligible to receive Bcl-2 family inhibitor therapy and for monitoring patient response to Bcl-2 family inhibitor therapy comprise assessment of the expression levels of the biomarker combinations set out in TABLES 1, 2, 3, 4, 5 or 6 in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive Bcl-2 family inhibitor therapy and of determination of patient response to the therapy.
    Type: Application
    Filed: December 4, 2007
    Publication date: August 21, 2008
    Inventors: Mark G. Anderson, Paul E. Kroeger, Saul Howard Rosenberg, Stephen K. Tahir, Christin Tse, John A. Wass